---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012991"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:53:24.926209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M

## Summary
- Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.
- Cash and equivalents $7.5M at Dec 31, 2025 ($3.2M prior year); funded into Q1 2027.
- Raised $15.4M gross in 2025/early 2026 including $4.125M private placement with insider participation.
- R&D expenses fell to $2.9M from $8.2M as STAR-1 acne study completed; SG&A up to $4.8M on marketing.
- Hired Kyra Peckaitis as VP Marketing; withdrew XYNGARI IND despite positive Phase 3 data.

## SEC filing metadata
- accession: 0001493152-26-012991
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/0001493152-26-012991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012991
- JSON: https://secwatch.observer/filing/0001493152-26-012991.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012991.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.
  - Period: year ended December 31, 2025
  - Result: reported results
  source text: Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/0001493152-26-012991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.